ATNM - actiniumpharma.com Revenue Growth YoY (Last 12 Months)

Graphic logo of Actinium Corp (ATNM)

Actinium Pharmaceuticals (ATNM) leads the development of advanced radiopharmaceuticals for the therapy of hematological tumors, actively advancing the Iomab-B project. The company's TTM revenue growth rate visualizes this progress, where the 38843.70 mark reflects the current state. A unique isotope delivery method will ensure complete pricing power, although the business currently relies heavily on external contractors for stable drug production.

Actinium Pharmaceuticals Inc - ATNM Sales Growth YoY (TTM) (period 02/11/2024 - 11/18/2026)

Actinium Pharma (ATNM) - metric breakdowns and financial figures

Fundamental company valuation:ATNM (Actinium Corp)
Flagship merchandise of Actinium Pharmaceuticals, Inc.

Investors are evaluating Actinium Pharmaceuticals (ATNM) through the lens of its unique positioning in radiopharmaceuticals. This metric measures the daily change in annual revenue over a rolling 12-month period, revealing the actual vector of operational growth. Analyzing the year-over-year sales growth percentage for TTM allows for tracking revenue acceleration prior to the market launch of Iomab-B. Complex isotope logistics minimize competition, making this indicator a key marker of commercial scaling. A stable trend will confirm the fundamental resilience of the business.